Company intelligence / Profile preview

AgoneX Biopharmaceuticals, Inc.

Santa Monica, California, United Statesagonexbio.com ↗

Ownership: Private
Development stage: Phase 2

Overview

AgoneX Biopharmaceuticals’ lead candidate AGX‑201 is a first-in-class small molecule that modulates histamine receptors to prevent migraines. The company has completed an IND filing with the FDA and was cleared to begin at Phase II for migraine. AGX‑201 is also in Phase I development for Alzheimer’s disease, with additional pipeline programs in earlier stages targeting neurodegenerative and neurological diseases. The company claims its approach may offer superior safety, efficacy, and cost compared to current CGRP antibody therapies.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules (notably histamine dihydrochloride)
Industry: Biotech

Drug pipeline

1 asset

AGX-201

Phase 2

Indications: Migraine

Beyond the preview

Go deeper on AgoneX Biopharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AgoneX Biopharmaceuticals, Inc..

Explore the full profile